Infectious complications of vascular anomalies treated with sirolimus: A systematic review
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.30758 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Rachel Kalbfell und 9 weiteren Autor:innen. Beteiligte Einrichtung: Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Pneumonia, Pneumocystis, Vascular Malformations. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background and objectives Initially developed as immunosuppressive agents, mammalian target of rapamycin (mTOR) inhibitors are currently used widely in the management of vascular malformations and tumors. The incidence of infectious complications in the vascular anomalies (VA) population is not well defined. The goal of this systematic review was to better define the types and severity of reported infectious complications in patients with VAs treated with mTOR inhibition.
Methods
This was a systematic review conducted following PRISMA guidelines evaluating all research articles focused on infectious complications in patients with VAs treated with sirolimus or everolimus. Thirty articles including 1182 total patients and 316 infections (in 291 unique patients) were ultimately included.
Results
The majority of infections were viral upper respiratory ( n = 137, 54%), followed by pneumonia ( n = 53, 20%), and cutaneous infections ( n = 20, 8%). There were six total infection‐related fatalities, which all occurred in patients younger than 2 years. Two cases of Pneumocystis jirovecii pneumonia (PJP) were reported. These were infants with kaposiform hemangioendothelioma (KHE) who were also treated with steroids and did not receive PJP prophylaxis. Almost one‐third ( n = 96, 32%) of infectious complications were graded 3–4 according to Common Terminology Criteria for Adverse Events (CTCAE) criteria. Details of patient age, subtype of VA, and timing of infection were lacking from many reports.
Conclusions
Most infectious complications reported in patients with VA on mTOR inhibitors were viral respiratory infections and non‐severe. Bacteremia, infectious fatalities, and PJP are exceedingly rare. Future studies are needed to clarify the spectrum of infectious risks in VA patients and to provide guidance for infection prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Pediatrics, Division of Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- St. Louis Children's Hospital, St. Louis, Missouri, USA.
- Department of Pediatrics, Division of Hematology/Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Pediatrics, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Pediatrics, Division of Hematology/Oncology, University of North Carolina, Chapel Hill, North Carolina, USA.
ORCID-Profile: Rachel Kalbfell, Alexandra J Borst, Julie Blatt, Bryan A Sisk
Zitieren
APA
Kalbfell, R., Cohen-Cutler, S., Grisham, E., Bereitschaft, C., Borst, A. J., Green, A. M., Willis, D. N., Yaeger, L., Blatt, J., & Sisk, B. A. (2024). Infectious complications of vascular anomalies treated with sirolimus: A systematic review. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30758
Vancouver
Kalbfell R, Cohen-Cutler S, Grisham E, Bereitschaft C, Borst AJ, Green AM, et al. Infectious complications of vascular anomalies treated with sirolimus: A systematic review. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30758
BibTeX
@article{Kalbfell2024,
author = {Kalbfell, Rachel and Cohen-Cutler, Sally and Grisham, Eric and Bereitschaft, Christine and Borst, Alexandra J and Green, Abby M and Willis, Daniel N and Yaeger, Lauren and Blatt, Julie and Sisk, Bryan A},
title = {Infectious complications of vascular anomalies treated with sirolimus: A systematic review},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.30758}
}
EUVIMED